SOPHiA GENETICS director reports share holdings

SOPHiA GENETICS SA director Troy Cox has filed an initial ownership report showing a substantial equity position in the company.

Rhea-AI Filing Summary

SOPHiA GENETICS SA director Troy Cox has filed an initial ownership report showing a substantial equity position in the company. He directly holds 309,019 ordinary shares, which include 33,784 ordinary shares to be delivered under a restricted share unit award that vests in full at the issuer’s next annual shareholder meeting, subject to his continued service.

He also holds several share option awards over ordinary shares. These include options over 11,500 shares at an exercise price of 4.0100 per share expiring on June 19, 2029, 162,740 shares at 4.1200 per share expiring on January 1, 2030, and 49,751 shares at 3.0400 per share expiring on June 18, 2035. The filing states that the share options are fully vested and exercisable.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Cox Troy

Role Director

Type	Security	Shares	Price	Value
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Share Option (Right to Buy)	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 223,991 contracts (Direct); Ordinary Shares — 309,019 shares (Direct)

Footnotes (3)

1. F1. Includes 33,784 ordinary to be delivered in settlement of a restricted share unit award ("RSU"). Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer. The RSUs were granted on June 18, 2025 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders.
2. F2. The share options are fully vested and exercisable.
3. F3. The share options were granted on June 18, 2025 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Troy Cox’s Form 3 filing for SOPHiA GENETICS (SOPH) show?

The filing shows Troy Cox’s initial beneficial ownership in SOPHiA GENETICS. He reports direct holdings of ordinary shares plus multiple share option awards and restricted share units, outlining his total equity exposure as a director of the company.

How many SOPHiA GENETICS ordinary shares does Troy Cox report owning?

Troy Cox reports direct ownership of 309,019 ordinary shares. This figure includes 33,784 ordinary shares to be delivered upon settlement of a restricted share unit award that vests in full at the company’s next annual shareholder meeting, subject to continued service.

What share options in SOPHiA GENETICS does Troy Cox hold according to the Form 3?

He holds several option grants over ordinary shares. These cover 11,500 shares at 4.0100, 162,740 shares at 4.1200, and 49,751 shares at 3.0400 per share, each with specified expiration dates between 2029 and 2035.

Are Troy Cox’s SOPHiA GENETICS share options vested and exercisable?

The filing states that the share options are fully vested and exercisable. This means he currently has the right to purchase the underlying ordinary shares at the respective exercise prices before the stated expiration dates, subject to standard option terms.

What restricted share units (RSUs) for SOPHiA GENETICS does Troy Cox report?

He reports 33,784 ordinary shares to be delivered upon settlement of a restricted share unit award. Each RSU represents one ordinary share and vests 100% at the issuer’s next scheduled annual meeting of shareholders, contingent on his continued service.

When were Troy Cox’s SOPHiA GENETICS share options and RSUs granted and when do they vest?

The RSUs and certain share options were granted on June 18, 2025. They vest 100% as of the date of SOPHiA GENETICS’ next scheduled annual meeting of shareholders, provided Troy Cox continues to serve the company through that vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 09:45 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cox Troy

(Last) (First) (Middle)

C/O SOPHIA GENETICS INC.

401 PARK DRIVE, FLOOR 5

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	309,019(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(2)	06/19/2029	Ordinary Shares	11,500	$4.01	D
Share Option (Right to Buy)	(2)	01/01/2030	Ordinary Shares	162,740	$4.12	D
Share Option (Right to Buy)	(3)	06/18/2035	Ordinary Shares	49,751	$3.04	D

Explanation of Responses:

1. Includes 33,784 ordinary to be delivered in settlement of a restricted share unit award ("RSU"). Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer. The RSUs were granted on June 18, 2025 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders.

2. The share options are fully vested and exercisable.

3. The share options were granted on June 18, 2025 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date.

Remarks:

Exhibit list - Exhibit 24 - Power of Attorney

	/s/ Elimara Brunetto as Attorney-in-Fact for Troy Cox	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)